Navigation Links
New High Purity Immunoglobulin Enters Phase III in Europe and the US
Date:2/16/2010

LACHEN, Switzerland, February 16 /PRNewswire/ --

- Octapharma to Set New Standards in IVIG Development, Focused on Improving Outcomes For Patients and Physicians

Octapharma AG today announced the start of the first of a series of Phase III studies for its new 10% high purity intravenous immunoglobulin (IVIG). The study will investigate the efficacy and safety of this novel immunoglobulin in the treatment of primary immune deficiency and, together with results from additional upcoming studies, will support its regulatory filing in Europe and the US.

Commenting on the start of the study, Kim Björnstrup, Deputy Chairman of Octapharma Group said, "The development of our novel 10% IVIG is part of our ongoing commitment to invest in the development of protein based immunotherapies and in particular in IgG preparations. For 25 years, our cutting-edge research programme has sought to develop new biological entities tailored specifically around the needs of clinicians and patients - delivering improved quality of life for patients and ease of delivery and management for hospitals."

"Octapharma's stated aim is not to develop just another IVIG brand but to invest extensive time and preclinical resources to ensure that the new IVIG will offer outstanding features, representing tangible added value for the patient and care giver, such as exceptional tolerability," added Kim Björnstrup.

The development of this pioneering high purity IVIG builds upon Octapharma's experience in the area of immunoglobulin products. octagam(R), Octapharma's current leading IVIG (an immune globulin human solution for intravenous administration) is registered in about 60 countries, including the EU and the US.

"Octapharma's new 10% IVIG will be a step forward in the evolution of IVIG products. In the development of the product, Octapharma has looked to optimise the characteristics of the product for improved patient outcomes, such as high tolerability even at high infusion rates. Pre-clinical studies and initial clinical experiences have confirmed that a favourable tolerability profile may be expected," commented the coordinating investigator of the study, Professor Michael Borte of Leipzig, Germany.

The Phase III study in primary immune deficiency represents the start of a series of planned studies to investigate Octapharma's new 10% IVIG for a range of neurologic and haematological conditions including idiopathic thrombocytopenic purpura (ITP), Guillain-Barré syndrome (GBS) and Kawasaki disease and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

About Primary Immune Deficiency

Primary immunodeficiencies are disorders in which part of the body's immune system is missing or do not function properly(1). As one of the most important functions of the normal immune system is to protect us against infection, patients with primary immunodeficiency diseases commonly have an increased susceptibility to infection(2) including severe ones such as pneumonia or sepsis. Most primary immunodeficiencies are genetic disorders; the majority are diagnosed in children under the age of one, although milder forms may not be recognised until adulthood. About 1 in 500 people are born with a primary immunodeficiency(1).

About Octapharma AG

Octapharma, a biopharmaceutical company, was founded in 1983. Its mission is to work for the safe and optimal usage of human proteins. Octapharma products are state-of-the-art within treatment of haemophilia, immune diseases, volume expansion and plasma transfusions. Octapharma's turnover in 2008 was EUR 886 million. Octapharma is a privately held company with headquarters in Lachen, Switzerland, and employs 2,500 people worldwide.

About octagam(R)

octagam(R) is a 5% (50 mg/mL) immune globulin (human) solution for intravenous administration (IVIG), currently registered in about 60 countries worldwide.

References

(1) Lim MS, Elenitoba-Johnson KS (2004). "The molecular pathology of primary immunodeficiencies". The Journal of molecular diagnostics: JMD 6 (2): 59-83. PMID 15096561.

    (2) Immune Deficiency Foundation.
http://www.primaryimmune.org/about_pi/about_pi.htm. Accessed January 2010.

SOURCE Octapharma AG


'/>"/>
SOURCE Octapharma AG
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Purity Products Releases Their Next Generation Lycopene Omega-3 Super Formula
2. Purity Products Releases Their Brand New Mediterranean Diet Resveratrol Formula
3. New Reagents from New England Biolabs Bring Purity and Increased Value to Sample Prep for Next Generation Sequencing
4. Purity Products Partners with Leading Vitamin D Expert to Create Next-Generation D3 Complex
5. Diet, Purity of Food Source Could be Keys to Improving Health of Hong Kong Toddlers
6. Watson-Marlow Releases Informative Video Featuring Showcased High Purity Pumps, Tubing and Fillers at Interphex 2009
7. Experimental Apartment in Beijing Achieves 99% Purity of Indoor Air
8. NSF International Certifies Purity of Four Mannatech Products
9. New technique improves purity of medicines
10. Immunoglobulin Can Predict Some Diabetic Complications
11. Minorities Not Treated at Higher-Quality Centers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Dickinson ... offers insurance and financial preparation services, is providing an update on a charitable ... , Rock City Rescue is a locally recognized nonprofit that provides shelter and ...
(Date:10/13/2017)... ... ... PurhealthRX , a leading Health and Nutrition Company, is announcing the ... spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the amount ... into liquid products, while reducing costs to end users. , The team of researchers ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset ... of specialty vendors and unique items from across the nation, this holiday-themed event will ... services offered by the VNA. The boutique will be open Saturday, November 4 ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Oct. 12, 2017 West Pharmaceutical Services, ... solutions for injectable drug administration, today announced that it ... opens on Thursday, October 26, 2017, and will follow ... business expectations at 9:00 a.m. Eastern Time. To participate ... (International). The conference ID is 94093362. ...
(Date:10/11/2017)... Oct. 11, 2017  True Health, a leader ... its effort during National Breast Cancer Awareness month ... risks. Research ... calculated that more than 10 million American women ... in BRCA1 or BRCA2 and have not had testing. ...
(Date:10/10/2017)... 2017   West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today shared the results of a study ... the intradermal administration of polio vaccines. The study results ... May 2017 by Dr. Ondrej Mach , Clinical ... Organization (WHO), and recently published in the journal ...
Breaking Medicine Technology: